EXEL

42.70

0.56% -0.24

Dopo l'orario di chiusura: 42.99 0.29 +0.68%

Exelixis Inc (EXEL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché EXEL Giù? Forum Previsione

Precedente Chiudi:

$42.94

Aprire:

$42.83

Volume 24 ore:

2.56M

Relative Volume:

0.99

Capitalizzazione di mercato:

$11.09B

Reddito:

$2.29B

Utile/perdita netta:

$677.90M

Rapporto P/E:

17.98

EPS:

2.3753

Flusso di cassa netto:

$779.77M

1 W Prestazione:

+0.78%

1M Prestazione:

-3.09%

6M Prestazione:

+12.52%

1 anno Prestazione:

+30.18%

Intervallo 1D:

$42.35

$43.52

Intervallo di 1 settimana:

$40.92

$44.28

Portata 52W:

$32.38

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Nome

Exelixis Inc

Settore

Healthcare (1112)

Industria

Biotechnology (621)

Telefono

(650) 837-7000

Indirizzo

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Dipendente

1,147

Cinguettio

@exelixisinc

Prossima data di guadagno

2025-07-28

Ultimi documenti SEC

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EXEL Exelixis Inc	42.70	11.15B	2.29B	677.90M	779.77M	2.3753
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Downgrade	BofA Securities	Neutral → Underperform
2025-11-18	Iniziato	Wolfe Research	Peer Perform
2025-11-03	Downgrade	Guggenheim	Buy → Neutral
2025-10-21	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-09-19	Ripresa	Barclays	Equal Weight
2025-09-17	Ripresa	Barclays	Equal Weight
2025-09-17	Iniziato	Goldman	Buy
2025-07-08	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Aggiornamento	Stephens	Equal-Weight → Overweight
2025-02-24	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Downgrade	Oppenheimer	Outperform → Perform
2024-12-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Downgrade	BofA Securities	Buy → Neutral
2024-10-16	Reiterato	RBC Capital Mkts	Outperform
2024-09-19	Iniziato	UBS	Neutral
2024-04-11	Downgrade	Barclays	Overweight → Equal Weight
2023-12-19	Iniziato	BTIG Research	Buy
2023-12-15	Iniziato	Citigroup	Buy
2023-09-26	Iniziato	H.C. Wainwright	Buy
2023-08-22	Reiterato	Oppenheimer	Outperform
2023-08-08	Iniziato	SVB Securities	Market Perform
2023-07-11	Ripresa	Morgan Stanley	Equal-Weight
2023-05-10	Ripresa	Piper Sandler	Overweight
2023-03-09	Iniziato	Wells Fargo	Overweight
2023-01-26	Iniziato	Credit Suisse	Outperform
2022-10-18	Iniziato	JMP Securities	Mkt Outperform
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-11-03	Ripresa	Jefferies	Buy
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Reiterato	H.C. Wainwright	Buy
2021-06-15	Iniziato	H.C. Wainwright	Buy
2021-05-18	Ripresa	Goldman	Sell
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-03-12	Iniziato	Wolfe Research	Outperform
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Iniziato	SunTrust	Buy
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-03-18	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Iniziato	Goldman	Neutral
2018-09-10	Iniziato	Morgan Stanley	Underweight
2018-05-11	Reiterato	Needham	Buy
2017-10-17	Reiterato	Needham	Buy
2017-10-17	Reiterato	RBC Capital Mkts	Outperform
2017-10-16	Reiterato	SunTrust	Buy
2017-09-22	Downgrade	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-09-12	Reiterato	Needham	Buy
2017-07-14	Iniziato	SunTrust	Buy
2017-03-31	Iniziato	Needham	Buy
2017-03-16	Iniziato	Oppenheimer	Perform
2017-02-28	Downgrade	Stifel	Buy → Hold
2016-11-03	Iniziato	Deutsche Bank	Buy
2016-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-09-15	Reiterato	Stifel	Buy

Mostra tutto

Exelixis Inc Borsa (EXEL) Ultime notizie

01:06 AM

Exelixis stock price target raised to $54 from $52 at H.C. Wainwright By Investing.com - Investing.com India

08:14 AM

08:01 AM

Exelixis stock price target raised to $54 from $52 at H.C. Wainwright - Investing.com

08:01 AM

07:44 AM

EXEL: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus

07:44 AM

07:01 AM

A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts - Benzinga

07:01 AM

Feb 11, 2026

Exelixis (NASDAQ:EXEL) Price Target Raised to $46.00 - MarketBeat

Feb 11, 2026

EXEL: Stifel Raises Price Target to $44 and Maintains Hold Ratin - GuruFocus

Feb 11, 2026

Exelixis (NASDAQ:EXEL) Price Target Raised to $35.00 - MarketBeat

Feb 11, 2026

Citizens maintains Exelixis stock rating on promising cancer treatment data By Investing.com - Investing.com Canada

Feb 11, 2026

EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus - Yahoo Finance UK

Feb 11, 2026

RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating - marketscreener.com

Feb 11, 2026

Citizens maintains Exelixis stock rating on promising cancer treatment data - Investing.com

Feb 11, 2026

Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 11, 2026

Essex Investment Management Co. LLC Raises Stock Position in Exelixis, Inc. $EXEL - MarketBeat

Feb 11, 2026

Decoding Exelixis Inc (EXEL): A Strategic SWOT Insight - GuruFocus

Feb 11, 2026